John E. Alessi

john-alessi

John E. Alessi

Associate

Boston | One International Place, 40th Floor, 100 Oliver Street, Boston, MA, United States of America 02110-2605
+1 617 728 7186 | +1 617 426 6567

| vCard | PDF

John E. Alessi focuses his practice on mergers and acquisitions. Mr. Alessi has significant experience representing public and private companies in matters relating to mergers and acquisitions, restructuring, and capital markets. He regularly represents clients from the technology and life sciences sectors, across a range of jurisdictions.

Prior to joining Dechert, Mr. Alessi was an attorney in the Boston office of an international law firm.

Experience
  • Biogen, Inc., in its spin-off of Bioverativ Inc., with an initial market capitalization of approximately US$4.8 billion.
  • Citrix Systems, Inc., in its spin-off and sale of its “GoTo” software business to LogMeIn, Inc., valued at approximately US$1.8 billion.
  • IntraLinks Holdings, Inc., in its auction and sale process resulting in a sale to Synchronoss Technologies, Inc., valued at approximately US$821 million.
  • Novell, Inc., in responding to an unsolicited acquisition offer in a process that resulted in an auction and sale of the company in a concurrent patent sale and merger valued at US$2.2 billion. 
  • Gilead Sciences, Inc., in its acquisition of clinical program asset from a German private biopharmaceutical company in a transaction worth up to US$470 million.
  • Broadcom Corporation in its US$165 million acquisition of a modem-related division of Japanese semiconductor manufacturer Renesas Electronics.
  • Vocus, Inc., in its auction and sale process resulting in a sale to GTCR valued at US$450 million.
  • Esselte in the sale to R.R. Donnelley & Sons Company of its North American operations valued at US$100 million.
  • Rhythmia Medical, Inc., in its US$265 million sale to Boston Scientific Corporation.
  • Broadcom Corporation in its US$3.7 billion acquisition of NetLogic Microsystems Inc.
  • Praecis Pharmaceuticals Incorporated in its sale and licensing of assets related to the development and manufacture of one of its marketed products to UK-based Speciality European Pharma Limited.
  • Spectrum Brands, Inc., in a US$350 million exchange offer of its public notes in connection with a negotiated settlement with certain of the company's significant noteholders with respect to a purported default on the notes.
  • Spectrum Brands, Inc., in a refinancing through a negotiated chapter 11 bankruptcy restructuring, including a recapitalization of approximately US$800 million in subordinated indebtedness.
  • Select Income REIT in its initial public offering.
  • The RMR Group, Inc., in its public offering by way of a distribution through its public shareholders.
  • Paradigm, Ltd., in its US$1 billion sale to Apax Partners and JMI Equity.
  • GSI Commerce, Inc., in its purchase of e-mail marketing software company e-Dialog, Inc., for US$157 million.
  • Acopia Networks in its sale to F5 Networks, Inc., for US$210 million.
  • Textron, Inc., in its sale of its pumps division to UK-based Clyde Blowers, Ltd., in a transaction valued at up to US$645 million.

Includes matters handled at Dechert or prior to joining the firm.

Education
  • Duke University, B.A., 1996
  • Columbia Law School, J.D., 2003
Admissions
  • Massachusetts
  • New York